{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T15:40:32Z","timestamp":1753890032780,"version":"3.41.2"},"reference-count":92,"publisher":"IMR Press","issue":"11","license":[{"start":{"date-parts":[[2022,11,15]],"date-time":"2022-11-15T00:00:00Z","timestamp":1668470400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>2020 and 2021 were disastrous years across the world, with the emergence of the severe acute respiratory syndrome coronavirus 2 (SARS\u2011CoV\u20112) virus as a pandemic, which continues to be a top global health issue. There are still many countries and regions struggling to fight coronavirus disease 2019 (COVID-19), and, with the emergence of the various variants of the virus, we are still far from considering this global pandemic over. In addition to having good diagnostic tools and a variety of vaccines with high efficacy, it is of utmost importance to develop effective antiviral drugs or therapies to battle COVID-19. Aptamers known as the next-generation targeting elements can offer promising opportunities in developing antiviral drugs against SARS-CoV-2. This is owing to their high specificity and affinity, making them ideal for targeting ligands and neutralizers to impede both, viral entry and replication or even further enhance the anti-infection effects in the infected host cells. Also, aptamers are extremely attractive as they can be rapidly synthesized and scalable with a lower production cost. This work provides in-depth discussions on the potential of aptamers in therapeutic applications, their mode of action, and current progress on the use of aptamer-based therapies against SARS-CoV-2 and other viruses. The article also discusses the limitations associated with aptamer-based SARS-CoV-2-antiviral therapy with several proposed ideas to resolve them. Lastly, theranostic applications of aptamer nanoformulated dendrimers against viral infections are discussed.<\/jats:p>","DOI":"10.31083\/j.fbl2711306","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T08:47:06Z","timestamp":1668588426000},"source":"Crossref","is-referenced-by-count":2,"title":["Aptamer-Mediated Antiviral Approaches for SARS-CoV-2"],"prefix":"10.31083","volume":"27","author":[{"given":"Kei Xian","family":"Tan","sequence":"first","affiliation":[{"name":"GenScript Biotech (Singapore) Pte. Ltd., 349248 Singapore, Singapore"}]},{"given":"Jaison","family":"Jeevanandam","sequence":"first","affiliation":[{"name":"CQM - Centro de Qu\u00edmica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"}]},{"given":"Jo\u00e3o","family":"Rodrigues","sequence":"first","affiliation":[{"name":"CQM - Centro de Qu\u00edmica da Madeira, MMRG, Universidade da Madeira, Campus da Penteada, 9020-105 Funchal, Portugal"},{"name":"School of Materials Science and Engineering, Center for Nano Energy Materials, Northwestern Polytechnical University, 710072 Xi\u2019an, Shaanxi, China"}]},{"given":"Michael K.","family":"Danquah","sequence":"first","affiliation":[{"name":"Department of Chemical Engineering, University of Tennessee, Chattanooga, TN 37996, USA"}]}],"member":"16242","published-online":{"date-parts":[[2022,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Zhu Z, Lian X, Su X, Wu W, Marraro GA, Zeng Y. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respiratory Research. 2020; 21: 224.","DOI":"10.1186\/s12931-020-01479-w"},{"key":"ref2","unstructured":"World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022. Available at: https:\/\/covid19.who.int (Accessed: 22 July 2022)."},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Jayamohan H, Lambert CJ, Sant HJ, Jafek A, Patel D, Feng H, et al. SARS-CoV-2 pandemic: a review of molecular diagnostic tools including sample collection and commercial response with associated advantages and limitations. Analytical and Bioanalytical Chemistry. 2021; 413: 49\u201371.","DOI":"10.1007\/s00216-020-02958-1"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Rotondo JC, Martini F, Maritati M, Caselli E, Gallenga CE, Guarino M, et al. Advanced Molecular and Immunological Diagnostic Methods to Detect SARS-CoV-2 Infection. Microorganisms. 2022; 10: 1193.","DOI":"10.3390\/microorganisms10061193"},{"key":"ref5","unstructured":"U.S Food and Drug Administration. Administration USFaD, Coronavirus (COVID-19) Update: FDA Authorizes Additional Oral Antiviral for Treatment of COVID-19 in Certain Adults. 2021. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-additional-oral-antiviral-treatment-covid-19-certain (Accessed: 23 July 2022)."},{"key":"ref6","unstructured":"U.S. Food and Drug Administration. Administration USFaD, Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. 2021. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 (Accessed: 23 July 2022)."},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Cully M. A tale of two antiviral targets - and the COVID-19 drugs that bind them. Nature Reviews Drug Discovery. 2022; 21: 3\u20135.","DOI":"10.1038\/d41573-021-00202-8"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Roberts JA, Duncan A, Cairns KA. Pandora\u2019s box: Paxlovid, prescribing, pharmacists and pandemic. Journal of Pharmacy Practice and Research. 2022; 52: 1\u20134.","DOI":"10.1002\/jppr.1799"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. New England Journal of Medicine. 2022; 386: 509\u2013520.","DOI":"10.1056\/NEJMoa2116044"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Kozlov M. Merck\u2019s COVID pill loses its lustre: what that means for the pandemic. Nature. 2021. (online ahead of print)","DOI":"10.1038\/d41586-021-03667-0"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Jiang S, Hillyer C, Du L. Neutralizing Antibodies against SARS-CoV-2 and other Human Coronaviruses. Trends in Immunology. 2020; 41: 355\u2013359.","DOI":"10.1016\/j.it.2020.03.007"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Tan KX, Danquah MK, Pan S, Yon LS. Binding Characterization of Aptamer-Drug Layered Microformulations and in Vitro Release Assessment. Journal of Pharmaceutical Sciences. 2019; 108: 2934\u20132941.","DOI":"10.1016\/j.xphs.2019.03.037"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Tan KX, Danquah MK, Sidhu A, Ongkudon CM, Lau SY. Towards targeted cancer therapy: Aptamer or oncolytic virus? European Journal of Pharmaceutical Sciences. 2017; 96: 8\u201319.","DOI":"10.1016\/j.ejps.2016.08.061"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Tan KX, Pan S, Jeevanandam J, Danquah MK. Cardiovascular therapies utilizing targeted delivery of nanomedicines and aptamers. International Journal of Pharmaceutics. 2019; 558: 413\u2013425.","DOI":"10.1016\/j.ijpharm.2019.01.023"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Jeevanandam J, Tan KX, Danquah MK, Guo H, Turgeson A. Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications\u2014the Role of Molecular Dynamics Simulation. Biotechnology Journal. 2020; 15: 1900368.","DOI":"10.1002\/biot.201900368"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Wandtke T, Wo\u017aniak J, and Kopi\u0144ski P. Aptamers in diagnostics and treatment of viral infections. Viruses. 2015; 7: 751\u2013780.","DOI":"10.3390\/v7020751"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Tan KX, Danquah MK, Sidhu A, Yon LS, Ongkudon CM. Aptamer-Mediated Polymeric Vehicles for Enhanced Cell-Targeted Drug Delivery. Current Drug Targets. 2018; 19: 248\u2013258.","DOI":"10.2174\/1389450117666160617120926"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Tan KX, Ujan S, Danquah MK. Colloidal formulation of aptamers for advanced therapeutic delivery. Materials for Biomedical Engineering. 2019; 479: 311\u2013329.","DOI":"10.1016\/B978-0-12-818433-2.00009-1"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Ng EWM, Shima DT, Calias P, Cunningham ET, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nature Reviews Drug Discovery. 2006; 5: 123\u2013132.","DOI":"10.1038\/nrd1955"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Riccardi C, Meyer A, Vasseur J-J, Cavasso D, Russo Krauss I, Paduano L, et al. Design, Synthesis and Characterization of Cyclic NU172 Analogues: A Biophysical and Biological Insight. International Journal of Molecular Sciences. 2020; 21: 3860.","DOI":"10.3390\/ijms21113860"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Sharma VR, Thomas SD, Miller DM, Rezzoug F. Nucleolin Overexpression Confers Increased Sensitivity to the Anti-Nucleolin Aptamer, as1411. Cancer Investigation. 2018; 36: 475\u2013491.","DOI":"10.1080\/07357907.2018.1527930"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Ismail SI, Alshaer W. Therapeutic aptamers in discovery, preclinical and clinical stages. Advanced Drug Delivery Reviews. 2018; 134: 51\u201364.","DOI":"10.1016\/j.addr.2018.08.006"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Ha\u00dfel SK, Mayer G. Aptamers as Therapeutic Agents: has the Initial Euphoria Subsided? Molecular Diagnosis and Therapy. 2019; 23: 301\u2013309.","DOI":"10.1007\/s40291-019-00400-6"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Nimjee SM, Sullenger BA. Therapeutic Aptamers: Evolving to Find their Clinical Niche. Current Medicinal Chemistry. 2020; 27: 4181\u20134193.","DOI":"10.2174\/0929867326666191001125101"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Musafia B, Oren-Banaroya R, and Noiman S. Designing Anti-Influenza Aptamers: Novel Quantitative Structure Activity Relationship Approach Gives Insights into Aptamer \u2013 Virus Interaction. PLoS ONE. 2014; 9: e97696.","DOI":"10.1371\/journal.pone.0097696"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Vaillant A, Juteau J, Lu H, Liu S, Lackman-Smith C, Ptak R, et al. Phosphorothioate Oligonucleotides Inhibit Human Immunodeficiency Virus Type 1 Fusion by Blocking gp41 Core Formation. Antimicrobial Agents and Chemotherapy. 2006; 50: 1393\u20131401.","DOI":"10.1128\/AAC.50.4.1393-1401.2006"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Cardin RD, Bravo FJ, Sewell AP, Cummins J, Flamand L, Juteau J, et al. Amphipathic DNA polymers exhibit antiviral activity against systemic Murine Cytomegalovirus infection. Virology Journal. 2009; 6: 214.","DOI":"10.1186\/1743-422X-6-214"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Neurath AR, Strick N, Li Y. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infectious Diseases. 2002; 2: 27.","DOI":"10.1186\/1471-2334-2-27"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Ditzler MA, Bose D, Shkriabai N, Marchand B, Sarafianos SG, Kvaratskhelia M, et al. Broad-spectrum aptamer inhibitors of HIV reverse transcriptase closely mimic natural substrates. Nucleic Acids Research. 2011; 39: 8237\u20138247.","DOI":"10.1093\/nar\/gkr381"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Macaya RF, Schultze P, Smith FW, Roe JA, Feigon J. Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution. Proceedings of the National Academy of Sciences. 1993; 90: 3745\u20133749.","DOI":"10.1073\/pnas.90.8.3745"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Hwang S, Sun H, Lee K, Oh B, Cha YJ, Kim BH, et al. 5\u2019-Triphosphate-RNA-independent activation of RIG-i via RNA aptamer with enhanced antiviral activity. Nucleic Acids Research. 2012; 40: 2724\u20132733.","DOI":"10.1093\/nar\/gkr1098"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Sullenger BA, Gallardo HF, Ungers GE, Gilboa E. Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation. Journal of Virology. 1991; 65: 6811\u20136816.","DOI":"10.1128\/jvi.65.12.6811-6816.1991"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Magbanua E, Zivkovic T, Hansen B, Beschorner N, Meyer C, Lorenzen I, et al. d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers. RNA Biology. 2013; 10: 216\u2013227.","DOI":"10.4161\/rna.22951"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zhu Q, Shibata T, Kabashima T, Kai M. Inhibition of HIV-1 protease expression in T cells owing to DNA aptamer-mediated specific delivery of siRNA. European Journal of Medicinal Chemistry. 2012; 56: 396\u2013399.","DOI":"10.1016\/j.ejmech.2012.07.045"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Zhou J, Neff CP, Swiderski P, Li H, Smith DD, Aboellail T, et al. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Molecular Therapy. 2013; 21: 192\u2013200.","DOI":"10.1038\/mt.2012.226"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Lee CH, Lee YJ, Kim JH, Lim JH, Kim J, Han W, et al. Inhibition of Hepatitis C Virus (HCV) Replication by Specific RNA Aptamers against HCV NS5B RNA Replicase. Journal of Virology. 2013; 87: 7064\u20137074.","DOI":"10.1128\/JVI.00405-13"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Yadavalli T, Agelidis A, Jaishankar D, Mangano K, Thakkar N, Penmetcha K, et al. Targeting Herpes Simplex Virus-1 gD by a DNA Aptamer can be an Effective New Strategy to Curb Viral Infection. Molecular Therapy - Nucleic Acids. 2017; 9: 365\u2013378.","DOI":"10.1016\/j.omtn.2017.10.009"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Chen H-L, Hsiao WH, Lee HC, Wu SC, Cheng JW. Selection and Characterization of DNA Aptamers Targeting All Four Serotypes of Dengue Viruses. PLoS ONE. 2015; 10: e0131240.","DOI":"10.1371\/journal.pone.0131240"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Binning JM, Wang T, Luthra P, Shabman RS, Borek DM, Liu G, et al. Development of RNA Aptamers Targeting Ebola Virus VP35. Biochemistry. 2013; 52: 8406\u20138419.","DOI":"10.1021\/bi400704d"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Lee KH, Zeng H. Aptamer-Based ELISA Assay for Highly Specific and Sensitive Detection of Zika NS1 Protein. Analytical Chemistry. 2017; 89: 12743\u201312748.","DOI":"10.1021\/acs.analchem.7b02862"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Yuan S, Zhang N, Singh K, Shuai H, Chu H, Zhou J, et al. Cross-Protection of Influenza a Virus Infection by a DNA Aptamer Targeting the PA Endonuclease Domain. Antimicrobial Agents and Chemotherapy. 2015; 59: 4082\u20134093.","DOI":"10.1128\/AAC.00306-15"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Gopinath SCB, Misono TS, Kawasaki K, Mizuno T, Imai M, Odagiri T, et al. An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. Journal of General Virology. 2006; 87: 479\u2013487.","DOI":"10.1099\/vir.0.81508-0"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Mumper RJ, Bell MA, Worthen DR, Cone RA, Lewis GR, Paull JRA, et al. Formulating a Sulfonated Antiviral Dendrimer in a Vaginal Microbicidal Gel Having Dual Mechanisms of Action. Drug Development and Industrial Pharmacy. 2009; 35: 515\u2013524.","DOI":"10.1080\/03639040802488097"},{"key":"ref44","unstructured":"NEC group. Innovators NS, NEC contributes to development of artificial DNA aptamer that binds to the novel coronavirus (SARS-CoV-2). 2021. Available at: https:\/\/www.nec.com\/en\/press\/202105\/global_20210506_02.html (Accessed: 27ss July 2022)."},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Valero J, Civit L, Dupont DM, Selnihhin D, Reinert LS, Idorn M, et al. A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry. Proceedings of the National Academy of Sciences. 2021; 118: e2112942118.","DOI":"10.1073\/pnas.2112942118"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host and Microbe. 2021; 29: 463\u2013476.e6.","DOI":"10.1016\/j.chom.2021.02.003"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Weisshoff H, Krylova O, Nikolenko H, D\u00fcngen H, Dallmann A, Becker S, et al. Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins. Heliyon. 2020; 6: e05421.","DOI":"10.1016\/j.heliyon.2020.e05421"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Song Y, Song J, Wei X, Huang M, Sun M, Zhu L, et al. Discovery of Aptamers Targeting the Receptor-Binding Domain of the SARS-CoV-2 Spike Glycoprotein. Analytical Chemistry. 2020; 92: 9895\u20139900.","DOI":"10.1021\/acs.analchem.0c01394"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Yang G, Li Z, Mohammed I, Zhao L, Wei W, Xiao H, et al. Identification of SARS-CoV-2-against aptamer with high neutralization activity by blocking the RBD domain of spike protein 1. Signal Transduction and Targeted Therapy. 2021; 6: 227.","DOI":"10.1038\/s41392-021-00649-6"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Neff CP, Akkina R. Targeted Delivery of Aptamers and siRNAs for HIV Prevention and Therapies in Humanized Mice. Humanized Mice for HIV Research. 2014; 397\u2013406.","DOI":"10.1007\/978-1-4939-1655-9_31"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Zhang L, Fang X, Liu X, Ou H, Zhang H, Wang J, et al. Discovery of sandwich type COVID-19 nucleocapsid protein DNA aptamers. Chemical Communications. 2020; 56: 10235\u201310238.","DOI":"10.1039\/D0CC03993D"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Chen Z, Wu Q, Chen J, Ni X, Dai J. A DNA Aptamer Based Method for Detection of SARS-CoV-2 Nucleocapsid Protein. Virologica Sinica. 2020; 35: 351\u2013354.","DOI":"10.1007\/s12250-020-00236-z"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Liu F, Wang C, Gao Y, Li X, Tian F, Zhang Y, et al. Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs. Molecular Diagnosis and Therapy. 2018; 22: 551\u2013569.","DOI":"10.1007\/s40291-018-0338-8"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"\u00c5kerstr\u00f6m S, Mirazimi A, Tan Y. Inhibition of SARS-CoV replication cycle by small interference RNAs silencing specific SARS proteins, 7a\/7b, 3a\/3b and S. Antiviral Research. 2007; 73: 219\u2013227.","DOI":"10.1016\/j.antiviral.2006.10.008"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Henzinger H, Barth DA, Klec C, Pichler M. Non-Coding RNAs and SARS-Related Coronaviruses. Viruses. 2020; 12:1374.","DOI":"10.3390\/v12121374"},{"key":"ref56","unstructured":"Ghosh S, Firdous SM, Nath A. siRNA could be a potential therapy for COVID-19. EXCLI Journal. 2020; 19: 528\u2013531."},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Asha K, Kumar P, Sanicas M, Meseko CA, Khanna M, Kumar B. Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections. Journal of Clinical Medicine. 2018; 8: 6.","DOI":"10.3390\/jcm8010006"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"Yang Y, Han Y, Sun Q, Cheng J, Yue C, Liu Y, et al. Au-siRNA@ aptamer nanocages as a high-efficiency drug and gene delivery system for targeted lung cancer therapy. Journal of Nanobiotechnology. 2021; 19: 54.","DOI":"10.1186\/s12951-020-00759-3"},{"key":"ref59","doi-asserted-by":"crossref","unstructured":"Zhang L, Mu C, Zhang T, Wang Y, Wang Y, Fan L, et al. Systemic Delivery of Aptamer-Conjugated XBP1 siRNA Nanoparticles for Efficient Suppression of HER2+ Breast Cancer. ACS Applied Materials & Interfaces. 2020; 12: 32360\u201332371.","DOI":"10.1021\/acsami.0c07353"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Dinis Ano Bom AP, da Costa Neves PC, Bonacossa de Almeida CE, Silva D, Missailidis S. Aptamers as Delivery Agents of siRNA and Chimeric Formulations for the Treatment of Cancer. Pharmaceutics. 2019; 11: 684.","DOI":"10.3390\/pharmaceutics11120684"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"Soldevilla MM, Meraviglia-Crivelli de Caso D, Menon AP, Pastor F. Aptamer-iRNAs as Therapeutics for Cancer Treatment. Pharmaceuticals. 2018; 11: 108.","DOI":"10.3390\/ph11040108"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Zhou J, Lazar D, Li H, Xia X, Satheesan S, Charlins P, et al. Receptor-targeted aptamer-siRNA conjugate-directed transcriptional regulation of HIV-1. Theranostics. 2018; 8: 1575\u20131590.","DOI":"10.7150\/thno.23085"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"Takahashi M, Burnett JC, Rossi JJ. Aptamer\u2013siRNA Chimeras for HIV. Gene Therapy for HIV and Chronic Infections. 2015; 211\u2013234.","DOI":"10.1007\/978-1-4939-2432-5_11"},{"key":"ref64","doi-asserted-by":"crossref","unstructured":"Wheeler LA, Vrbanac V, Trifonova R, Brehm MA, Gilboa-Geffen A, Tanno S, et al. Durable Knockdown and Protection from HIV Transmission in Humanized Mice Treated with Gel-formulated CD4 Aptamer-siRNA Chimeras. Molecular Therapy. 2013; 21: 1378\u20131389.","DOI":"10.1038\/mt.2013.77"},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Saify Nabiabad H, Amini M, Demirdas S. Specific delivering of RNAi using Spike\u2019s aptamer\u2010functionalized lipid nanoparticles for targeting SARS\u2010CoV\u20102: a strong anti\u2010Covid drug in a clinical case study. Chemical Biology and Drug Design. 2022; 99: 233\u2013246.","DOI":"10.1111\/cbdd.13978"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nature Reviews Drug Discovery. 2010; 9: 537\u2013550.","DOI":"10.1038\/nrd3141"},{"key":"ref67","doi-asserted-by":"crossref","unstructured":"Thevendran R, Sarah S, Tang T, Citartan M. Strategies to bioengineer aptamer-driven nanovehicles as exceptional molecular tools for targeted therapeutics: a review. Journal of Controlled Release. 2020; 323: 530\u2013548.","DOI":"10.1016\/j.jconrel.2020.04.051"},{"key":"ref68","doi-asserted-by":"crossref","unstructured":"Li L, Xu S, Yan H, Li X, Yazd HS, Li X, et al. Nucleic acid aptamers for molecular diagnostics and therapeutics: advances and perspectives. Angewandte Chemie International Edition. 2021; 60: 2221\u20132231.","DOI":"10.1002\/anie.202003563"},{"key":"ref69","doi-asserted-by":"crossref","unstructured":"Verhoef JJF, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discovery Today. 2014; 19: 1945\u20131952.","DOI":"10.1016\/j.drudis.2014.08.015"},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Ishida T, Kiwada H. Anti-polyethyleneglycol Antibody Response to PEGylated Substances. Biological and Pharmaceutical Bulletin. 2013; 36: 889\u2013891.","DOI":"10.1248\/bpb.b13-00107"},{"key":"ref71","doi-asserted-by":"crossref","unstructured":"Bouchard PR, Hutabarat RM, Thompson KM. Discovery and Development of Therapeutic Aptamers. Annual Review of Pharmacology and Toxicology. 2010; 50: 237\u2013257.","DOI":"10.1146\/annurev.pharmtox.010909.105547"},{"key":"ref72","doi-asserted-by":"crossref","unstructured":"Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nature Reviews Drug Discovery. 2017; 16: 181\u2013202.","DOI":"10.1038\/nrd.2016.199"},{"key":"ref73","doi-asserted-by":"crossref","unstructured":"Svenson S, Tomalia DA. Dendrimers in biomedical applications\u2014reflections on the field. Advanced Drug Delivery Reviews. 2012; 64: 102\u2013115.","DOI":"10.1016\/j.addr.2012.09.030"},{"key":"ref74","doi-asserted-by":"crossref","unstructured":"Kesharwani P, Jain K, Jain NK. Dendrimer as nanocarrier for drug delivery. Progress in Polymer Science. 2014; 39: 268\u2013307.","DOI":"10.1016\/j.progpolymsci.2013.07.005"},{"key":"ref75","doi-asserted-by":"crossref","unstructured":"Vacas-C\u00f3rdoba E, Maly M, De la Mata FJ, G\u00f3mez R, Pion M, Mu\u00f1oz-Fern\u00e1ndez M\u00c1. Antiviral mechanism of polyanionic carbosilane dendrimers against HIV-1. International Journal of Nanomedicine. 2016; 11: 1281\u20131294.","DOI":"10.2147\/IJN.S96352"},{"key":"ref76","doi-asserted-by":"crossref","unstructured":"Romanowski EG, Yates KA, Paull JRA, Heery GP, Shanks RMQ. Topical Astodrimer Sodium, a Non-Toxic Polyanionic Dendrimer, Demonstrates Antiviral Activity in an Experimental Ocular Adenovirus Infection Model. Molecules. 2021; 26: 3419.","DOI":"10.3390\/molecules26113419"},{"key":"ref77","doi-asserted-by":"crossref","unstructured":"Sep\u00falveda-Crespo D, Serram\u00eda MJ, Tager AM, Vrbanac V, G\u00f3mez R, De La Mata FJ, et al. Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16. Nanomedicine: Nanotechnology, Biology and Medicine. 2015; 11: 1299\u20131308.","DOI":"10.1016\/j.nano.2015.04.013"},{"key":"ref78","doi-asserted-by":"crossref","unstructured":"Maciel D, Guerrero-Beltr\u00e1n C, Ce\u00f1a-Diez R, Tom\u00e1s H, Mu\u00f1oz-Fern\u00e1ndez M, Rodrigues J. New anionic poly(alkylideneamine) dendrimers as microbicide agents against HIV-1 infection. Nanoscale. 2019; 11: 9679\u20139690.","DOI":"10.1039\/C9NR00303G"},{"key":"ref79","doi-asserted-by":"crossref","unstructured":"Ardestani MS, Fordoei AS, Abdoli A, Ahangari Cohan R, Bahramali G, Sadat SM, et al. Nanosilver based anionic linear globular dendrimer with a special significant antiretroviral activity. Journal of Materials Science: Materials in Medicine. 2015; 26: 179.","DOI":"10.1007\/s10856-015-5510-7"},{"key":"ref80","doi-asserted-by":"crossref","unstructured":"Falanga A, Del Genio V, Kaufman EA, Zannella C, Franci G, Weck M, et al. Engineering of Janus-Like Dendrimers with Peptides Derived from Glycoproteins of Herpes Simplex Virus Type 1: Toward a Versatile and Novel Antiviral Platform. International Journal of Molecular Sciences. 2021; 22: 6488.","DOI":"10.3390\/ijms22126488"},{"key":"ref81","doi-asserted-by":"crossref","unstructured":"Bayat M, Taherpour AA, Elahi SM. Molecular interactions between PAMAM dendrimer and some medicines that suppress the growth of hepatitis virus (Adefovir, Entecavir, Telbivudine, Lamivudine, Tenofovir): a theoretical study. International Nano Letters. 2019; 9: 231\u2013244.","DOI":"10.1007\/s40089-019-0277-3"},{"key":"ref82","unstructured":"Antunes NMPR. Fighting Dengue and Zika using novel Glycodendrimer-encapsulated metal nanoparticles as viral inhibitors [master\u2019s thesis]. Universidade da Madeira. 2021."},{"key":"ref83","doi-asserted-by":"crossref","unstructured":"Lembo D, Donalisio M, Civra A, Argenziano M, Cavalli R. Nanomedicine formulations for the delivery of antiviral drugs: a promising solution for the treatment of viral infections. Expert Opinion on Drug Delivery. 2018; 15: 93\u2013114.","DOI":"10.1080\/17425247.2017.1360863"},{"key":"ref84","doi-asserted-by":"crossref","unstructured":"Fr\u00f6hlich T, Hahn F, Belmudes L, Leidenberger M, Friedrich O, Kappes B, et al. Synthesis of Artemisinin-Derived Dimers, Trimers and Dendrimers: Investigation of their Antimalarial and Antiviral Activities Including Putative Mechanisms of Action. Chemistry - a European Journal. 2018; 24: 8103\u20138113.","DOI":"10.1002\/chem.201800729"},{"key":"ref85","doi-asserted-by":"crossref","unstructured":"McCarthy TD, Karellas P, Henderson SA, Giannis M, O\u2019Keefe DF, Heery G, et al. Dendrimers as Drugs:\u2009 Discovery and Preclinical and Clinical Development of Dendrimer-Based Microbicides for HIV and STI Prevention. Molecular Pharmaceutics. 2005; 2: 312\u2013318.","DOI":"10.1021\/mp050023q"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Jiang Y-H, Emau P, Cairns JS, Flanary L, Morton WR, McCarthy TD, et al. SPL7013 gel as a topical microbicide for prevention of vaginal transmission of SHIV89. 6P in macaques. AIDS Research & Human Retroviruses. 2005; 21: 207\u2013213.","DOI":"10.1089\/aid.2005.21.207"},{"key":"ref87","unstructured":"Rupp R, Rosenthal SL, Stanberry LR. VivaGel\u2122(SPL7013 Gel): A candidate dendrimer\u2013microbicide for the prevention of HIV and HSV infection. International Journal of Nanomedicine. 2007; 2: 561\u2013566."},{"key":"ref88","doi-asserted-by":"crossref","unstructured":"Khaitov M, Nikonova A, Shilovskiy I, Kozhikhova K, Kofiadi I, Vishnyakova L, et al. Silencing of SARS\u2010CoV\u20102 with modified siRNA\u2010peptide dendrimer formulation. Allergy. 2021; 76: 2840\u20132854.","DOI":"10.1111\/all.14850"},{"key":"ref89","doi-asserted-by":"crossref","unstructured":"Mignani S, Shi X, Karpus A, Lentini G, Majoral J-P. Functionalized Dendrimer Platforms as a New Forefront Arsenal Targeting SARS-CoV-2: An Opportunity. Pharmaceutics. 2021; 13: 1513.","DOI":"10.3390\/pharmaceutics13091513"},{"key":"ref90","doi-asserted-by":"crossref","unstructured":"Farzin L, Sadjadi S, Sheini A, Mohagheghpour E. A nanoscale genosensor for early detection of COVID-19 by voltammetric determination of RNA-dependent RNA polymerase (RdRP) sequence of SARS-CoV-2 virus. Microchimica Acta. 2021; 188: 121.","DOI":"10.1007\/s00604-021-04773-6"},{"key":"ref91","doi-asserted-by":"crossref","unstructured":"Zhou J, Neff CP, Liu X, Zhang J, Li H, Smith DD et al. Systemic Administration of Combinatorial dsiRNAs via Nanoparticles Efficiently Suppresses HIV-1 Infection in Humanized Mice. Molecular Therapy. 2011; 19: 2228-2238.","DOI":"10.1038\/mt.2011.207"},{"key":"ref92","unstructured":"Vivian JS, Towards HIV Sensing: The Development of Electrochemical DNA\/RNA Aptamer Biosensors on Dendrimer-Gold Platforms [master\u2019s thesis]. University of Johannesburg. 2013."}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/11\/10.31083\/j.fbl2711306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T12:32:47Z","timestamp":1732710767000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/27\/11\/10.31083\/j.fbl2711306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,15]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022]]}},"alternative-id":["S2768-6701(22)00675-X"],"URL":"https:\/\/doi.org\/10.31083\/j.fbl2711306","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"type":"print","value":"2768-6701"},{"type":"electronic","value":"2768-6698"}],"subject":[],"published":{"date-parts":[[2022,11,15]]},"article-number":"306"}}